South Korea’s response to the pandemic has been praised, achieving success through rigorous preparation and rapid response, attributed to decisive government action, aggressive track-and-trace policies and almost immediate access to PCR tests.
Leading South Korea’s innovative biotechnology industry is Seegene, a world leader in molecular diagnostics, specialising in multiplex polymerase chain reaction (PCR) assays since 2000. As a global pioneer in the in vitro diagnostic (IVD) market, its innovative patented molecular technologies and integrated automation solutions have resulted in Seegene being pivotal in providing molecular IVD solutions across Europe, with in excess of 1000 platforms being used routinely for enteric, respiratory, sexually transmitted infection (STI) and human papillomavirus (HPV) screening.
Since early on in the pandemic, Seegene has been a regular focus of the world press for its ability to rapidly develop and manufacture real-time PCR test kits for COVID-19.
So, how did Seegene do it? Learn more in the August issue of Pathology in Practice.
